Since approval, the ClearView 3 has been used by many surgeons across the United States. Both surgeon and patient feedback has been exceptional, with early post-operative outcomes meeting or exceeding the performance of previously approved multifocal IOLs. During the FDA trial and early commercial implant experience, the ClearView 3 has proven that its next generation proprietary design lends itself to excellent distance, intermediate and near visual acuities and a lower rate of dysphotopsias than existing premium IOL implants.
Lenstec is a leading designer and manufacturer of intraocular Lenses (IOLs) to treat patients with a range of vision disorders. Founded in 1992, the company is dedicated to advancing possibilities for ophthalmic professionals and their patients worldwide.
More information about the ClearView 3 and Lenstec’s line of Precision Series IOLs is available at www.Lenstec.com and www.ClearViewLens.com.